EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Cytek Biosciences's Enterprise Value is $505.3 Mil.
Cytek Biosciences's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2023 was $0.5 Mil. Therefore, Cytek Biosciences's EV-to-FCF for today is 1,112.94.
The historical rank and industry rank for Cytek Biosciences's EV-to-FCF or its related term are showing as below:
CTKB'
s EV-to-FCF Range Over the Past 10 Years
Min: -333.41 Med: -57.77 Max: 6836.56
Current: 1112.94
During the past 5 years, the highest EV-to-FCF of Cytek Biosciences was 6836.56. The lowest was -333.41. And the median was -57.77.
CTKB's EV-to-FCF is ranked worse than 98.64% of 369
companies
in the Medical Devices & Instruments industry
Industry Median: 27.47
vs CTKB: 1112.94
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
The historical data trend for Cytek Biosciences's EV-to-FCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Cytek Biosciences's EV-to-FCF
For the Medical Devices subindustry, Cytek Biosciences's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Cytek Biosciences's EV-to-FCF Distribution in the Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Cytek Biosciences's EV-to-FCF distribution charts can be found below:
* The bar in red indicates where Cytek Biosciences's EV-to-FCF falls into.
Cytek Biosciences's current Enterprise Value is $505.3 Mil.
Cytek Biosciences's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.5 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
Cytek Biosciences's PE Ratio for today is calculated as:
Cytek Biosciences's share price for today is $5.76.
Cytek Biosciences's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.090.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.
Cytek Biosciences EV-to-FCF Related Terms
Thank you for viewing the detailed overview of Cytek Biosciences's EV-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.
Cytek Biosciences (Cytek Biosciences) Business Description
Cytek Biosciences Inc is a cell analysis solutions company advancing the next generation of cell analysis tools by leveraging novel technical approaches. Its core instruments, the Aurora and Northern Lights systems, are the first full-spectrum flow cytometers able to deliver high-resolution, high-content, and high-sensitivity cell analysis by utilizing the full spectrum of fluorescence signatures from multiple lasers to distinguish fluorescent tags on single cells. Its FSP platform addresses the inherent limitations of other technologies by providing a higher density of information with greater sensitivity, more flexibility, and increased efficiency, all at a lower cost for performance.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
CTKB has been successfully added to your 